These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6369888)

  • 1. [A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia].
    Karniol IG; Giampietro AC; Moura DS; Vilela WA; Oliveira MA; Zuardi AW
    Acta Psiquiatr Psicol Am Lat; 1983 Dec; 29(4):261-6. PubMed ID: 6369888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stable remission of tardive dyskinesia by L-dopa.
    Ludatscher JI
    J Clin Psychopharmacol; 1989 Feb; 9(1):39-41. PubMed ID: 2565346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia.
    Simpson GM; Yadalam KG; Stephanos MJ
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):49S-51S. PubMed ID: 2906069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB; Caligiuri MP
    J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin E in the treatment of tardive dyskinesia.
    Akhtar S; Jajor TR; Kumar S
    J Postgrad Med; 1993; 39(3):124-6. PubMed ID: 7914238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics].
    Hebenstreit GF; Hoffmann H; Hoffmann W; Pittner H
    Wien Klin Wochenschr; 1986 Jun; 98(12):388-92. PubMed ID: 2874663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
    Dekundy A; Lundblad M; Danysz W; Cenci MA
    Behav Brain Res; 2007 Apr; 179(1):76-89. PubMed ID: 17306893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose pyridoxine in tardive dyskinesia.
    DeVeaugh-Geiss J; Manion L
    J Clin Psychiatry; 1978 Jun; 39(6):573-5. PubMed ID: 350860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of intravenous metoclopramide in 81 patients with tardive dyskinesia.
    Doongaji DR; Jeste DV; Jape NM; Sheth AS; Apte JS; Vahia VN; Desai AB; Parikh MD; Rathi LG; Ghandi MH; Parikh RM; Thatte S; Bharadwaj J
    J Clin Psychopharmacol; 1982 Dec; 2(6):376-9. PubMed ID: 7174860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tiapride in the treatment of irreversible tardive dyskinesia--initial experiences].
    Leblhuber F; Reisecker F; Bengesser G
    Z Gerontol; 1987; 20(1):49-51. PubMed ID: 2883781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxprenolol in schizophrenic patients with tardive dyskinesia: a double-blind placebo-controlled, crossover study.
    Karniol IG; Portela W
    Braz J Med Biol Res; 1982 Dec; 15(6):389-94. PubMed ID: 6135468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dopamine-receptor stimulators and neuroleptic-induced dyskinesia (author's transl)].
    Ringwald E
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Nov; 11(6):294-8. PubMed ID: 33397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin E in the treatment of tardive dyskinesia.
    Elkashef AM; Ruskin PE; Bacher N; Barrett D
    Am J Psychiatry; 1990 Apr; 147(4):505-6. PubMed ID: 1969247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A crossover study of lecithin treatment of tardive dyskinesia.
    Gelenberg AJ; Dorer DJ; Wojcik JD; Falk WE; Brotman AW; Leahy L
    J Clin Psychiatry; 1990 Apr; 51(4):149-53. PubMed ID: 2182613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levetiracetam in tardive dyskinesia.
    Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L
    Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.